drugset / Trial / NCT06033118
Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC
NaSingle-groupOpen-labelTreatment
Summary
The Purpose of This Study is to Evaluate the Efficacy and Safety of Gemox combined with Anlotinib and Sintilimab as first-lineTherapy for Patients With advanced combined hepatocellular-cholangiocarcinoma.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2025-07-31
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Gemcitabine | Small molecule | 1 g | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 g | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |